Y Intercept Hong Kong Ltd Increases Stake in Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI)

Y Intercept Hong Kong Ltd boosted its stake in shares of Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) by 155.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 32,359 shares of the company’s stock after acquiring an additional 19,713 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Maravai LifeSciences were worth $176,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of MRVI. JPMorgan Chase & Co. raised its position in Maravai LifeSciences by 1,172.4% during the third quarter. JPMorgan Chase & Co. now owns 4,050,245 shares of the company’s stock valued at $33,658,000 after acquiring an additional 3,731,924 shares in the last quarter. Point72 DIFC Ltd purchased a new stake in shares of Maravai LifeSciences in the third quarter valued at approximately $22,108,000. Royce & Associates LP increased its position in shares of Maravai LifeSciences by 130.4% in the third quarter. Royce & Associates LP now owns 908,778 shares of the company’s stock valued at $7,552,000 after buying an additional 514,332 shares in the last quarter. Quantinno Capital Management LP increased its position in shares of Maravai LifeSciences by 610.2% in the third quarter. Quantinno Capital Management LP now owns 336,527 shares of the company’s stock valued at $2,797,000 after buying an additional 289,141 shares in the last quarter. Finally, Systematic Financial Management LP increased its position in shares of Maravai LifeSciences by 14.7% in the third quarter. Systematic Financial Management LP now owns 1,612,161 shares of the company’s stock valued at $13,397,000 after buying an additional 206,499 shares in the last quarter. 50.25% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms have recently commented on MRVI. Royal Bank of Canada cut their price objective on Maravai LifeSciences from $17.00 to $13.00 and set an “outperform” rating for the company in a research report on Friday, November 8th. Bank of America cut their price objective on Maravai LifeSciences from $9.00 to $8.00 and set a “buy” rating for the company in a research report on Monday. Guggenheim began coverage on Maravai LifeSciences in a research report on Thursday, December 19th. They issued a “neutral” rating for the company. The Goldman Sachs Group cut Maravai LifeSciences from a “neutral” rating to a “sell” rating and cut their price objective for the company from $7.00 to $4.25 in a research report on Thursday, December 5th. Finally, Wolfe Research began coverage on Maravai LifeSciences in a research report on Thursday, November 14th. They issued a “peer perform” rating for the company. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $9.28.

Maravai LifeSciences Stock Performance

Shares of NASDAQ:MRVI opened at $2.81 on Thursday. The business’s 50 day moving average price is $4.70 and its 200-day moving average price is $6.35. The firm has a market capitalization of $709.60 million, a PE ratio of -1.71 and a beta of -0.08. The company has a debt-to-equity ratio of 0.89, a current ratio of 10.74 and a quick ratio of 9.94. Maravai LifeSciences Holdings, Inc. has a 1 year low of $2.72 and a 1 year high of $11.56.

Insiders Place Their Bets

In other Maravai LifeSciences news, General Counsel Kurt Oreshack sold 25,000 shares of the business’s stock in a transaction on Friday, January 31st. The stock was sold at an average price of $5.03, for a total transaction of $125,750.00. Following the transaction, the general counsel now owns 167,618 shares of the company’s stock, valued at approximately $843,118.54. The trade was a 12.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.63% of the stock is currently owned by corporate insiders.

Maravai LifeSciences Profile

Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company’s products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.